Raptor Pharma (RPTP) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Raptor Pharmaceuticals (RPTP) PT Slashed to $5 at Wedbush; Difficulties Ahead
February 27, 2015 8:38 AM ESTWedbush analyst David Nierengarten reiterated an Underperform rating and cut his price target on Raptor Pharmaceuticals (NASDAQ: RPTP) to $5.00 (from $7.00) following Q4 results, saying decrease sales hints at difficulties ahead.
Nierengarten commented, "Raptor reported $17.3M in ww sales of Procysbi in 4Q, in line with our $16.9M... More
